AMEX:LABD   Direxion Daily S&P Biotech Bear 3X Shares
Since LABU Long cut short this week from the previous analysis (ran up 15% and stopped at 3% profit). Entering LABD Long as the next big idea for 5:1 R:R.

Fundamentally, I felt this was the right trade long before once the pharmy companies come out with official vaccines that will leave the majority of the industry in despair as only a select few in the industry will continue to benefit from the Covid story.

Related Ideas

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.